Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
RESEARCH TRIANGLE PARK, N.C., July 16 Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.
Mr. Moch brings more than 25 years of experience in managing and financing biomedical technologies, and has played a key role in building several life science companies. In this newly-created position, Mr. Moch will be responsible for overseeing corporate and financial strategy, business development and operations, reporting to George Painter, Ph.D., Chimerix's President and Chief Executive Officer.
"Ken is a seasoned industry executive whose depth and breadth of leadership experience significantly strengthens the Chimerix management team," said Dr. Painter. "I look forward to working closely with Ken on a shared vision for advancing Chimerix's pipeline of potent broad spectrum antiviral compounds, and building an organization focused on advancing important new medicines."
"With a rich pipeline of next-generation antiviral drug candidates, productive platform technology, an extraordinary library of new leads and supportive top-tier investors, Chimerix combines deep assets with the scientific heritage necessary to emerge at the forefront of antiviral drug development," said Mr. Moch. "I am excited to join this veteran team. We have the opportunity to create much-needed new pharmaceutical products with promise in a broad range of challenging viral diseases."
Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services to life sciences companies, where he most recently served as President and CEO of BioMedical Enterprises, Inc., a developer and marketer of orthopaedic memory metal implants. Previously, he was Managing Director, Healthcare Investment Banking at ThinkEquity Partners. In 1995, Mr. Moch joined Alteon Inc., a biotechnology company specializing in small molecule therapeutics for cardiovascular aging and diabetic complications, where he served as President and CEO from 1998 to 2005. Mr. Moch served as President and CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells. Prior, he was co-founder and Vice President of The Liposome Company, Inc. Earlier in his career, Mr. Moch was a management consultant with McKinsey & Company, Inc. Mr. Moch holds a degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.
Chimerix, Inc. discovers, develops and commercializes antiviral therapeutics with enhanced pharmaceutical properties for the treatment of a range of life-threatening diseases. Leveraging a powerful lipid technology, Chimerix is able to develop drug candidates with oral availability or topical applications with increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events. The company's lead compound, CMX001, has shown promise as a broad-spectrum antiviral drug and is currently being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination, as well as for the treatment of infections that cause morbidity and mortality in immunocompromised patients such as cytomegalovirus (CMV) and BK virus. Chimerix's pipeline includes an anti-HIV drug, CMX157, in late-stage preclinical studies. Chimerix is also advancing programs in hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.
SOURCE Chimerix, Inc.
You May Also Like